If a patient's medication inhibits glycoprotein IIb/IIIa receptors on platelets, which consequence follows during an injury that causes bleeding?

💡 Explanation

Inhibition of glycoprotein IIb/IIIa receptors reduces platelet aggregation, because these receptors mediate platelet cross-linking via fibrinogen binding. Therefore, reduced platelet aggregation occurs, rather than increased thromboxane production or enhanced fibrinogen binding, which would promote clotting.

• If a patient reports diminished fine touch discrimination in their fingertips following median nerve compression at the carpal tunnel, which consequence follows regarding the activation of mechanoreceptors?
• Why does excessive fibrinolysis increase the risk of hemorrhage following tissue plasminogen activator (tPA) administration for stroke?
• Why does administering a beta-1 adrenergic receptor antagonist to a patient with heart failure reduce cardiac output?
• If a desert hiker, severely dehydrated and with elevated plasma osmolality, develops a mutation that completely disables aquaporins in the collecting ducts of their kidneys, which consequence follows?
• If a growth factor receptor mutation in cancer cells disables the intrinsic apoptosis pathway while nutrient supply decreases, which consequence follows?
• Why does thyroid hormone (TH) production often remain stable despite variations in thyrotropin-releasing hormone (TRH) from the hypothalamus?